Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DeCode Genetics has begun enrolling subjects in a phase I clinical trial for DG041, the company's developmental compound for the treatment of atherosclerosis of the extremities, commonly known as peripheral arterial occlusive disease.
Subscribe to our email newsletter
The ascending-dose, placebo controlled trial will evaluate the safety as well as the pharmacokinetic and pharmacodynamic profile of DG041, DeCode’s novel, first-in-class, orally-administered small molecule.
In preclinical studies, DG041 has been shown to be a selective and potent antagonist of the EP3 receptor for prostaglandin E2 (PGE2), inhibiting human platelet aggregation in a dose-dependent manner. DeCode selected EP3 as a target in peripheral arterial occlusive disease (PAOD) through its population genetics research, which linked variations in the gene encoding EP3 to increased risk of the disease.
“DG041 is the second compound we have entered into clinical trials, and the most advanced to have been developed entirely from our own target and drug discovery capabilities,” said Kari Stefansson, CEO of DeCode. “Our preclinical data on DG041 were very encouraging and we look forward to sharing the results of this trial in a few months time.”